Asceneuron

Developer of small molecules for the treatment of neurodegenerative diseases

placeLausanne, Vaud, Switzerland calendar_todayFounded 2012 groups3 employees language asceneuron.com

Registered entities

Investor mix

12 investors on record; lead investors include Sofinnova Partners, Novo Holdings.

Investor typeCountShare
Venture capital650%
Private equity18%
Other / undisclosed542%
Coming soon